ohad

ARRY suffered some blows with its RA drugs but I still think they have a very broad and diverse pipeline. With platform companies such as ARRY, the most important thing is patience- statistically, they should have good news as well.

Ohad

Regarding Incyte, An interesting Filing on 16 October, you can watch it under Incyte->Investor relations -> SEC filings.
what’s interesting about it is, and I quote:

“The Board of Directors has adopted, subject to stockholder approval, an amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 200,000,000 to 400,000,000. The Board of Directors recommends that the Company’s stockholders approve this amendment.”

Ohad, I would love to hear your thoughts on the matter.

What is your take on ARRY. Are you selling it or still keeping it. Its in 52 week low right now.

I always look forward to read your articles. Keep up the good work.

Thanks
Denny

I really like ARQL at the current valuation and think it has a lot more to offer with the AKIP platform, but you have to remember that for now, it is still a one drug company.
The next big catalyst is results from the Tarceva combination study. It’s hard to predict but the data on this combination at the World Conference on Lung Cancer is pretty encouraging.

ohad

Haven’t looked at them for a while. Generally, I don’t like locally administered drugs. I am also not sure they picked the right gene, but time will tell.

ohad

As you might know already I enjoy your blogs Ive not bought INCY as of yet, nervous I guess, but I was watching ARQL and was considering buying in under $4, but it got a pop today from UBS upgrade although volume wise, it wasnt a high and most buying was early. BVF, a major investor sold a chunk of their shares last month. Any opinion on its current valuation?

What do you think about Genvec(GNVC). It has started moving.

Its lead product, TNFerade, is in late stage development for pancreatic cancer with positive clinical data to date and potential in other indications. On the other hand, the company’s underlying technology for vaccine and gene delivery has established a promising long term pipeline for multiple therapeutic indications.

Thanks
Denny

SPPI depends on Zevalin, which is a very frustrating drug because it shows great activity but physicians and patients choose not to use it due to its radioactivity. I certainly hope things will change following the recent data and first line approval, but I am not sure about that.
Financially, the company looks cheap with half of its market cap in cash, but a lot of that is going to be invested in marketing.

RIGL - Another tough decision. With the mixed negative data in TNF failures, it seems less attractive even though the potential for a drug like R788 is in TNF-naive patients.
There is probably going to be a licensing deal next year so buying ahead of that might prove wise. I am still on the sidelines.

ohad

IMGN is facing the most important catalyst it has ever had this December with the T-DM1 data in 3rd line patients.

Ohad

The decision is based primarily on the value of Curagen’s pipeline and the cash dowry it brought to the merger. With respect to CLDX’s programs, I didn’t delve too deep into their pipeline. I am not a big fan of cancer vaccines, but their lead program looks pretty good, including the rationale and the clinical data. They also seem to have good antibody capabilities, I wish they focused more on that side and just vaccines.

Ohad

Immunogen has almost tripled. Why do you plan on buying more immgn in the future? Do you expect a catalyst to move the stock soon?

congratulations to the performance of your portfolio and your helpful comments.

Interesting to see that you intend to keep Curagen after the merger with Celldex. Your opinion to Curagens pipeline is published. What are your thoughts about the Celldex pipeline? Merriman Curhan Ford sees very much potential.

Kind regards
Toby

I like PBTH’s technology, they have very nice proof of concept with the women fertility project (FSH-CTP).

Ohad